Filtered By:
Source: American Heart Journal
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 491 results found since Jan 2013.
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics
ConclusionThe LoDoCo2 Trial will provide information on the efficacy and safety of low-dose colchicine for secondary prevention in patients with stable coronary artery disease.
Source: American Heart Journal - November 7, 2019 Category: Cardiology Source Type: research
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the ARISTOTLE trial
ConclusionsIn patients with AF on oral anticoagulants, prior GIB was associated with an increased risk of subsequent major GIB but not stroke, intracranial bleeding, or all-cause mortality. For the key outcomes of stroke, hemorrhagic stroke, death, and major bleeding, we found no evidence that the treatment effect (apixaban vs. warfarin) was modified by a history of GIB.
Source: American Heart Journal - November 2, 2019 Category: Cardiology Source Type: research
Patterns of Amiodarone use and outcomes in clinical practice for atrial fibrillation
ConclusionsUse of amiodarone among AF patients in community practice is highly variable. More than 2 out of 3 patients treated with amiodarone appeared to be eligible for a different AAD.
Source: American Heart Journal - October 24, 2019 Category: Cardiology Source Type: research
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease
Publication date: Available online 23 October 2019Source: American Heart JournalAuthor(s): Robert C. Welsh, Eric D. Peterson, Raffaele De Caterina, Christoph Bode, Bernard Gersh, John W. EikelboomAbstractFor four decades, anti-thrombotic therapy with aspirin has been a cornerstone of secondary prevention for patients with chronic atherosclerotic cardiovascular disease (ASCVD). Unfortunately, despite the use of evidence-based therapies, patients with ASCVD continue to have recurrent major adverse cardiovascular (CV) events including death, myocardial infarction and stroke -- at a rate of approximately 2–4% per year. To co...
Source: American Heart Journal - October 24, 2019 Category: Cardiology Source Type: research
Outcome impact of different tranexamic acid regimens in cardiac surgery with cardiopulmonary bypass (OPTIMAL): Rationale, design, and study protocol of a multi-center randomized controlled trial
ConclusionsThe study is designed to identify a TxA dose with maximal efficacy and minimal complications. We hypothesize that the high dose has superior efficacy and non-inferior safety to the low dose.
Source: American Heart Journal - October 22, 2019 Category: Cardiology Source Type: research
Incidence and predictors of atrial fibrillation episodes as detected by implantable loop recorder in patients at risk From the LOOP study
ConclusionA considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research
Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
ConclusionsThe majority of TECOS participants with ASCVD and T2D were overweight or obese, yet overweight or obese class I individuals had lower CV risk than those who were under/normal weight. These results suggest the presence of an obesity paradox, but this paradox may reflect an epidemiological artifact rather than a true negative association between normal weight and clinical outcomes.
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research
Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
ConclusionsIn this observational analysis of T2D and ASCVD, baseline beta-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic beta-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205).
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research
Sex-specific Cardiac Phenotype and Clinical Outcomes in Patients with Hypertrophic Cardiomyopathy
ConclusionsOur results suggest that sex-specific differences in LV geometry, hyper-contractility and diastolic function, not greater degree of LV myopathy, contribute to a higher, age-independent risk of diastolic HF in women with HCM.Graphical abstract
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research
T effect of low dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design and baseline characteristics
ConclusionThe LoDoCo2 Trial will provide information on the efficacy and safety of low dose colchicine for secondary prevention in patients with stable coronary artery disease.
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research
Claims-based cardiovascular outcome identification for clinical research: Results from seven large randomized cardiovascular clinical trials
ConclusionsClaims- vs. site-based (+CEC) follow-up identified similar overall cardiovascular event rates, despite meaningful differences in the events detected. Randomized treatment effects were similar using the two methods, suggesting claims data could be used to support clinical research leveraging routinely-collected data. This approach may lead to more effective evidence generation, synthesis, and appraisal of medical products and inform the strategic approaches toward the National Evaluation System for Health Technology.
Source: American Heart Journal - September 12, 2019 Category: Cardiology Source Type: research
Small-for-gestational-age birth is linked to cardiovascular dysfunction in early childhood
ConclusionsThis study shows that infants born SGA present an early and subtle cardiovascular dysfunction compared to AGA controls. These alterations are strongly related to weight at birth. Finally, breastfeeding exerts an important protective and beneficial cardiovascular effect.
Source: American Heart Journal - September 12, 2019 Category: Cardiology Source Type: research
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease - a meta-analysis of randomized clinical trials
ConclusionsIn patients with atherosclerotic artery disease, the benefit of ticagrelor-based therapies was confined to patients treated for CAD. The drug significantly reduced the risk for all-cause death and MI without excess risk of bleeding in these patients. In consideration of limitations of subgroup analyses, these results need further validation.
Source: American Heart Journal - September 2, 2019 Category: Cardiology Source Type: research
Long-Term (10-Year) Outcomes of Stenting or Bypass Surgery for Acute Coronary Syndromes and Stable Ischemic Heart Disease With Unprotected Left Main Coronary Artery Disease
ConclusionsIn patients with LMCA disease, we have identified no significant interaction between the acuity of clinical indication and the relative treatment effect of PCI versus CABG on 10-year clinical outcomes.
Source: American Heart Journal - August 22, 2019 Category: Cardiology Source Type: research
Association of 25-hydroxyvitamin D with incident coronary heart disease in the reasons for geographic and racial differences in stroke (REGARDS) study
ConclusionsLower plasma 25(OH)D concentrations were associated with higher risk of incident CHD. In contrast to prior studies, these associations did not differ by race.
Source: American Heart Journal - August 21, 2019 Category: Cardiology Source Type: research
